A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
Status: Recruiting
Location: See all (11) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up.
• Provided written informed consent to participate in this study.
Locations
United States
Arizona
Banner MD Anderson Cancer Center
RECRUITING
Gilbert
California
Stanford University
RECRUITING
Stanford
Connecticut
Yale University
RECRUITING
New Haven
Illinois
Robert H Lurie Cancer Center
RECRUITING
Chicago
Kansas
University of Kansas Cancer Center
RECRUITING
Westwood
Massachusetts
Dana Farber Cancer Institute
RECRUITING
Boston
Maryland
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
NOT_YET_RECRUITING
Baltimore
North Carolina
Duke University Medical Center - Division of Hematologic Malignancies
RECRUITING
Durham
Oregon
Oregon Health and Science University Knight Cancer Institute
RECRUITING
Portland
Texas
UT Southwestern Medical Center
RECRUITING
Dallas
Wisconsin
Froedtert Hospital and the Medical College of Wisconsin
RECRUITING
Milwaukee
Contact Information
Primary
Sadie Swift
clinicaltrials@miltenyi.com
617-218-0044
Backup
Paris Jamiel
clinicaltrials@miltenyi.com
617-218-0044
Time Frame
Start Date: 2024-05-15
Estimated Completion Date: 2041-12-01
Participants
Target number of participants: 150
Treatments
Long-term Follow-Up
No intervention
Related Therapeutic Areas
Sponsors
Leads: Miltenyi Biomedicine GmbH